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Abstract: Electrochemotherapy (ECT) of head and neck cancer can be particularly tricky because 
the Otolaryngologist has to be able to manage many different pathological conditions: small or 
large cutaneous nodules located on the skin of the upper or lower face; subcutaneous or deep 
seated tumors in proximity of vital structures and small or large mucosal lesions of the oral cavity 
or the oropharynx. Each of these situations requires specific treatment modalities ranging from 
procedures that can be conducted under local anesthesia with the use of the standard fixed-
geometry electrodes, to procedures that require general anesthesia, prophylactic tracheotomy 
and electroporation with the variable geometry.
The success of ECT in the head and neck area is strictly related to the capability of complete 
electroporation of the tumor nodules. The higher percentages of objective response are obtained 
in the skin areas, where the possibilities of complete coverage of the tumor mass is easier; while 
areas that cannot be easily exposed and reached with the electrodes, such as the oropharynx, 
or deep seated tumors show lower but still encouraging percentages of objective response. 
The development of new electrodes and the improvement of the procedures will increase the 
effectiveness of ECT in these peculiar conditions.
  
CURRENT PERSPECTIVES
Electrochemotherapy (ECT) is currently 
reserved to the palliative local treatment 
of cutaneous, subcutaneous or deep 
seated tumors of any kind of histology nor 
suitable to for standard treatments, the 
pain relief of tumor masses or the control 
of bleeding lesions (1). These pathological 
conditions can be particularly devastating 
in the head and neck area, where the 
standard treatments employed can add 
disabilities and worsen the residual quality 
of life in these patients (2).
Previous studies have proven the 
effectiveness of ECT in melanoma 
and non-melanoma skin cancers, with 
percentages of objective response verging 
100% in basal cell carcinomas (BCC) and 
with healing of the treated lesions without 
damage of the surrounding tissues and 
minimal or nil impact on the aesthetic and 
function of the head and neck subsites (3).
The treatment of the oral and oropharyngeal 
lesions is more complex and depends on 
the capability to cover with the electric field 
all the tumoral bed. Thus, small lesions 
located in easily attainable areas such as 
oral cheek, floor of the mouth, internal lip, 
mobile tongue can be successfully treated 
with standard or finger electrodes; while 
larger nodules with complex tridimensional 
growth or located in the tongue base or 
oropharynx cannot be totally covered with 
the fixed geometry electrodes (2).
Despite these technical difficulties the 
percentages of objective response are 
encouraging (56% in the EURECA study) 
(4) and will be further improved with the 
development of new electrodes capable to 
completely electroporate tumors located 
in these particular areas or with the use 
of the single electrodes and the variable 
geometry (2).
The application of the variable geometry is 
particularly indicated for the treatment of 
head and neck deep seated tumors. These 
lesions are not simply hidden under the 
mucosal or skin visible surface, but they 
can be also located near vital structures 
(large blood vessels, cranial nerves), 
bone structures or in limited spaces. The 
24
determination of the adequate position for 
each single electrode and the sequence of 
the electric pulses deliverance during the 
procedure can be planned with specific 
softwares and Navigation Systems (5).
TREATMENT MODALITIES
Even if ECT in head and neck can be 
applied to the treatment of any kind of 
tumor site (cutaneous, subcutaneous, 
mucosal or deep seated) the choice of 
drug delivery, type of anesthesia and type 
of electrodes depend on the number, size, 
location and patient’s general condition 
(Table 1) (2). 
In general, when the tumors are located in 
the upper face or scalp, and are few (< 3 cm 
)and less than 2 cm in size, the procedure 
can be conducted under local anesthesia, 
both drugs (bleomycin or cisplatin) can be 
used according to the Standard Operating 
Procedures (SOP) (1), and the choice of 
the electrode depending on the nodules’ 
morphology and thickness or depth of 
invasion; while in case of more than 3 
nodules and larger than 2 cm it is better 
to proceed under general anesthesia and 
with bleomycin given intravenously.
In case of tumors located in the lower 
face or neck, intraoral or deep seated 
the procedure must be performed 
under general anesthesia because 
of the possibility of severe pain and 
muscle contractions; the  choice of drug 
administration and type of electrodes 
follow the SOPs (1).
Moreover, in case of intraoral or 
oropharyngeal lesions, a profilactic 
Figure 1 Primary BCC (left) and the response 6 months after 2 cycles of ECT (right)
Figure 2 Primary SCC (left) and the response 2 months after ECT (right)
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tracheotomy has to be considered due to 
the risk of swelling of the soft tissues.
CONTRAINDICATIONS
Contraindications to ECT in head and 
neck are the same of the SOPs (1) with 
the adjunct of macroscopic infiltration of 
the internal jugular vein or carotid artery 
because of the risk of blowout secondary 
to tumor necrosis induced by ECT (Table 
2). 
Moreover, attention must be paid in the 
treatment of full-thickness lesions of the 
cheek or peristomal recurrences because 
of the risk of salivary fistulas, or in the 
treatment of full-thickness lesions of the 
lip for the risk of labial incompetence (2,6). 
FUTURE PERSPECTIVES
Usually, ECT is a safe treatment in head 
Table 2 Absolute and relative contraindication for ECT in the head and neck area
Clinical situation Absolute contraindication Relative contraindication
Major vessel tumor infiltration Macroscopic infiltration of the 
walls of the internal jugular vein 
or carotid artery
Difficulties with local/general 
anesthesia
Yes
Allergy to bleomycin or cisplatin Yes
Cumulative dose of bleomycin >240,000 IU/m2
Full-thickness lesions of the chin, 
cheek, or lip,
Peristomal lesions
High risk of salivary fistula and/or 
labial incompetence
Cardiac arrhythmias, pacemaker Thorax application <7 cm Head neck application
(>30 cm from heart)
Pulmonary function (Fibrosis) Bleomycin i.v. <30 % O2 delivery
Bleomycin i.t.
Hematology
(PLT <70,000/mm3, INR >1,5)
Verify type of electrodes
Renal function
(Creatinine <150 μmol/l)
Bleomycin i.t.
Adequate hydration
Table 1 Treatment modalities for cancers of the head and neck area
Treatment Site, Number, Size Anesthesia Drug administration Electrode
Modality A Head, face
< 3 nodules
< 2 cm
Local ± Sedation Bleomycin i.t./i.v.
Cisplatin i.t.
Plate (if superficial)
Row needle, 
Hexagonal, Finger (if 
deep
Modality B Head, face
> 3 nodules
> 2 cm
General Bleomycin i.v. Row needle, 
Hexagonal
Modality C Cheek, Chin, Neck,
Intraoral,
Deep seated
Any number
Any size
General Bleomycin i.t./i.v.
Cisplatin i.t.
Row needle, 
Hexagonal, Finger
Variable geometry
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and neck cancer patients because it 
results in minimal or null aesthetic  and 
functional compromise and leads to 
healing of treated tumor lesions without 
damage to the surrounding healthy 
tissues. Therefore, particular attention 
must be reserved to elderly patients 
because the risk of severe side effects and 
necrosis can be higher due to increased 
serum levels of bleomycin, induced by the 
reduction of total body water and a decline 
in glomerular filtration rate (7). In order to 
avoid these possible complications, some 
authors have already proposed a reduced 
dose of bleomycin (10.000 IU/m2) in elderly 
patients, instead of the standard dose of 
15.000 IU/m2, since the serum clearance 
curve of bleomycin is slower (less than 
500 ml/min) in elderly population (7).
The effectiveness of ECT in the treatment 
of cutaneous and subcutaneous tumor 
nodules, is high, with reported percentages 
of objective response approaching 100% 
(3); for this reason a future role for ECT 
as a first-line treatment of head and neck 
cancer, particularly in elderly patients, 
or as neo-adjuvant treatment for those 
cases in which surgical procedures and/or 
radiotherapy would be too devastating in 
achieving proper oncological results can 
be considered, even if randomized clinical 
trials are still necessary to confirm this 
possibility. 
Although ECT is highly efficient on treated 
nodules, it remains a local treatment 
having no apparent antitumor effects 
on non-treated distant nodules, even 
though it has been demonstrated that 
electroporation induces inflammation of 
the treated tissue and then activation of 
the immune system (8).
The combination of ECT and 
immunotherapy may have a long-term 
effect on local and systemic cancer 
eradication and seems to be a future 
perspective (9,10).
Similarly, anti-programmed cell death 
protein 1 (PD1) antibodies are also of 
great interest as they prevent the inhibitory 
effect on T cell functions of the interaction 
between PD1 (on T cells) and PD1 ligand 
(on tumor cells). Thus, a combination of 
ECT with anti-PD1 antibodies could be an 
elegant way to destroy the initial nodule 
while raising efficient antitumor responses 
to ultimately eliminate remaining and 
circulating cancer cells (8).
Alternatively, immune stimulation through 
electrogenetherapy (EGT) has also raised 
great hope for the treatment of cancer. 
Sersa et al. recently proposed a model 
of combination of ECT with peritumoral 
IL-12 electrotransfer; ECT boosted with 
immunogene electrotransfer could be 
considered a sort of in situ vaccination 
to potentiate not only death of the ECT-
treated tumor nodule but also to activate 
the immune system toward the same 
tumor cells on distant metastases where 
it can exert its immunological actions (11).
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